Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS ) on this product, Teva expects to launch this product in